


IC-KDA 2023

International Conference of the Korean Dementia Association

November 24-25, 2023 | BEXCO, Busan, Republic of Korea




PROGRAM BOOK

THE FIRST DONEPEZIL TRANSDERMAL PATCH

DONERION[®]

Donepezil 87.5mg/175mg **PATCH**

“Improved convenience
by *twice weekly*”



- ▶ **THREE LAYERS OF ULTRA THIN FILM**
REDUCES SKIN IRRITATION DURING ATTACHMENT.^{3,4,5}
- ▶ DECREASED PLASMA FLUCTUATION OF DONEPEZIL COMPARED TO **ORAL MEDICATION.**¹
- ▶ IMPROVED PATIENT COMPLIANCE VIA **TWICE WEEKLY SIMPLE APPLICATION.**²
- ▶ **IMPROVED CONVENIENCE** WITH SMALL AND THIN PATCH FORMULATION.³

References.

1. Data on File, Celltrion (Result from CSR of Phase I)
2. Donerion patch 87.5mg / 175mg (Donepezil) Insert paper
3. Republic of Korea registered patent 10-1796771
4. New Excellent Technology Award(NET). Available at https://www.netmark.or.kr/sub4/pop_tech_detail.asp?recv_seq=20141097, accessed on 09 June, 2022.
5. Korea Drug Research Association Award (KDRA). Available at <https://www.kdra.or.kr/website/03web03.php?d=History>. Accessed on 09 June, 2022.

OT2022-22



IC-KDA 2023

International Conference of
the Korean Dementia Association

CONTENTS

Overview	02
Welcome Message	03
Committee	04
Program at a Glance	05
Daily Program	06
Invited Speakers	11
Poster Exhibition	14
Floor Plan	32
Information	33
Exhibitions	36
Sponsors	38

Overview

Title	IC-KDA 2023 (International Conference of the Korean Dementia Association)
Dates	November 24–25, 2023
Venue	BEXCO, Busan, Republic of Korea
Host Organizer	Korean Dementia Association
Official Language	English
Website	www.ickda.org



Welcome Message

Dear Colleagues,

On behalf of the Korean Dementia Association (KDA), I would like to express my heartfelt appreciation to all our community members for your unwavering commitment to dementia research and education.

It is both an honor and a pleasure to inaugurate the International Conference of the Korea Dementia Association (IC-KDA 2023), set to take place at the BEXCO Convention Center in Busan, Korea, from November 24th to 25th, 2023.

This conference will serve as an invaluable platform for discussing the most recent advancements and challenges in dementia research. It offers an opportunity to explore emerging topics and forge connections with professionals across related disciplines. In light of the growing dementia patient population linked to an aging society, we aim to share groundbreaking research and insights from world-renowned experts. These exchanges are expected to significantly contribute to our conference theme, "Beyond Boundaries: Advancing Global Dementia Solutions".

Our agenda will include 16 comprehensive sessions, including the Plenary Session, Invited Session, Korea-Taiwan Joint Symposium, and Luncheon Symposium. Furthermore, a Poster Session will offer emerging dementia researchers an avenue to engage in meaningful dialogue.

We are confident that the conference will provide numerous opportunities for intellectual enrichment, knowledge sharing, and global networking. Beyond the academic offerings, I encourage you to immerse yourself in the vibrant culture of Busan, known for its exquisite beaches, lively markets, and delicious cuisine.

Thank you for your participation and we wish you an enriching and valuable experience.

Dong Won Yang, MD, PhD
Chairman, Board of directors
Korean Dementia Association



Committee

Position	Name	Affiliation
Organizing committee, Chair	Dong Won Yang	The Catholic University of Korea, College of Medicine
Organizing committee, Vice-chair	Young Chul Yoon	Chung-Ang University, College of Medicine
Academic committee, Chair	So Young Moon	Ajou University School of Medicine
Academic committee, Vice-chair	Kunho Lee	Chosun University, Department of Biomedical Science
	Hui Jin Ryu	Konkuk University Medical Center, Department of Neurology
General secretary	YongSoo Shim	The Catholic University of Korea, College of Medicine
Academic secretary	Geon Ha Kim	Ewha Womans University, College of Medicine
Organizing committee members	Kee Hyung Park	Gachon University, School of Medicine
	Hojin Choi	Hanyang University College of Medicine
	Haeri Na	Bobath Memorial Hospital, Department of Neurology
	Jae-Sung Lim	Asan Medical Center, Department of Neurology
Academic committee members	Jae-Won Jang	Kangwon National University School of Medicine
	Chi-Hun Kim	Hallym University College of Medicine
	Ko Woon Kim	Jeonbuk National University, School of Medicine
	Jeewon Suh	National Medical Center, Department of Neurology
	Hyemin Jang	Seoul National University Hospital, Department of Neurology
	Jaeho Kim	Hallym University College of Medicine
	Young Ho Park	Seoul National University College of Medicine
	Byong Seok Ye	Yonsei University College of Medicine
	Na-Yeon Jung	Pusan National University School of Medicine
	Yun Kyung Kim	KIST, Brain Science Institute
	Yong Jeong	KAIST, Department of Bio and Brain Engineering
	Jae Gwan Kim	GIST, Department of Biomedical Science and Engineering
	Won-Seok Choi	Chonnam National University, School of Biological Sciences and Technology
	Soh-Jeong Yang	Severance Hospital of Yonsei University Health System, Department of Neurology
	Juhee Chin	Samsung Medical Center, Department of Neurology

Program at a Glance

Time	Friday, November 24	Saturday, November 25	
Room	301 Grand Ballroom	205 Summit Hall	301 Grand Ballroom
08:25-08:30		Korea-Taiwan Joint Symposium Opening Remark	
08:30-09:00		Korea-Taiwan Joint Symposium 1	
09:00-09:30			
09:30-10:30	Session 1 Gut-brain Axis and Neuroinflammation in Dementia	Session 4 The Recent Issues in Clinical Neuropsychology	
10:30-10:40	Opening Ceremony	Korea-Taiwan MOU	Coffee Break
10:40-10:50		Korea-Taiwan Joint Symposium Closing Remark	
10:50-11:30	Plenary Session I		Plenary Session III
11:30-12:10	Plenary Session II		Plenary Session IV
12:10-13:00	Luncheon Symposium 1		Luncheon Symposium 2
13:00-14:00	Poster Session 1		Poster Session 2
14:00-15:30	Session 2 Blood-based Biomarkers for AD in Clinical Practice		Session 5 Update in FTD (Including FTD Cohort Study)
15:30-15:50	Coffee Break		Coffee Break
15:50-17:20	Session 3 Update in Treatment of Dementia		Session 6 Pathogenesis of Non-AD Dementia
17:20-	Presidential Dinner (Invited Only)		Closing Ceremony

Daily Program

Friday, November 24

09:00-10:30	Session 1 : Gut-Brain Axis and Neuroinflammation in Dementia Chairpersons Won-Seok Choi (Chonnam National University, Republic of Korea) Hoo Won Kim (Chosun University, Republic of Korea)	301 Grand Ballroom
09:00-09:30	Modern Koch's Postulates Applied to Bacterial Pathogenesis of Alzheimer's Disease Jan Potempa (Jagiellonian University, University of Louisville School of Dentistry, Poland/USA)	
09:30-10:00	Fecal Microbiota Transplantation in Patients with Dementia Seong Hye Choi (Inha University College of Medicine, Republic of Korea)	
10:00-10:30	ApoE Isoform-and Microbiota-Dependent Progression of Neurodegeneration in a Mouse Model of Tauopathy Dong-oh Seo (Washington University in St.Louis, USA)	
10:30-10:50	Opening Ceremony	301 Grand Ballroom
10:50-11:30	Plenary Session I Chairperson Kunho Lee (Chosun University, Republic of Korea)	301 Grand Ballroom
10:50-11:30	Pathogenesis and Early Diagnosis of Neurodegenerative Disease Keqiang Ye (Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences (CAS), China)	
11:30-12:10	Plenary Session II Chairperson Dong Won Yang (The Catholic University of Korea, Republic of Korea)	301 Grand Ballroom
11:30-12:10	Update on Plasma Biomarkers in Alzheimer's Disease Kaj Blennow (University of Gothenburg, Sweden)	
12:10-13:00	Luncheon Symposium 1 Chairperson Jae-Hong Lee (Asan Medical Center, Republic of Korea)	301 Grand Ballroom
12:10-12:35	Alzheimer's Disease Biomarkers Towards a New Era in the Diagnosis and Treatment of AD (Supported by Eisai) Jaeho Kim (Hallym University College of Medicine, Republic of Korea)	

12:35-13:00 Neurotrophic Approaches in Dementia: A Closer Look at Cerebrolysin
(Supported by Daewoongbio)
Chi-Hun Kim (Hallym University Sacred Heart Hospital, Republic of Korea)

13:00-14:00 Poster Session 1

201-204

14:00-15:30 Session 2 : Blood-based Biomarkers for AD in Clinical Practice 301 Grand Ballroom
Chairpersons
SangYun Kim (Seoul National University Bundang Hospital, Republic of Korea)
Seong-Ho Koh (Hanyang University Guri Hospital, Republic of Korea)

14:00-14:30 Implementation of High Performance Blood Biomarkers in Routine Clinical Care for the
Evaluation of Individuals with Cognitive Impairment
Joel Braunstein (C2N, USA)

14:30-15:00 Plasma Biomarkers of Neurodegenerative Diseases toward Clinical Practice(MagQu)
Charles Shieh-Yueh Yang (MagQu, Taiwan)

15:00-15:30 AlzOn: The Real World Example of Blood-based Biomarker Test Utility in Clinical Practice
Sungmin Kang (PeopleBio, Republic of Korea)

15:50-17:20 Session 3 : Update in Treatment of Dementia 301 Grand Ballroom
Chairpersons
Kee Hyung Park (Gachon University College of Medicine, Republic of Korea)
Sang Won Seo (Sungkyunkwan University, Republic of Korea)

15:50-16:20 Advances in AD Experimental Therapeutics
Alireza Atri (Banner Sun Health Research Institute (AZ) & Harvard Medical School (MA), USA)

16:20-16:50 Gene Therapy for Neurodegenerative Diseases
Jae young Lee (ToolGen, Republic of Korea)

16:50-17:20 Neuromodulation for Gliopathy in Alzheimer's Disease
Tae Kim (GIST, Republic of Korea)

17:20 - Presidential Dinner Nurimaru
(Invited Only)

Saturday, November 25

08:25-08:30	Korea-Taiwan Joint Symposium Opening Remark Dong Won Yang (The Catholic University of Korea, Republic of Korea)	205 Summit Hall
08:30-09:30	Korea-Taiwan Joint Symposium 1 Chairpersons SangYun Kim (Seoul National University Bundang Hospital, Republic of Korea) Jong-Ling Fuh (National Yang Ming Chiao Tung University, Taiwan)	205 Summit Hall
08:30-08:50	Can Fluid Biomarker Testings Change the Diagnosis and Management of Dementia? Yung Shuan Lin (Taipei Veterans General Hospital, Taiwan)	
08:50-09:10	Alzheimer's Disease Biomarkers: Towards a New Era in the Diagnosis and Treatment of AD Based on Blood Biomarkers Seong-Ho Koh (Hanyang University Guri Hospital, Republic of Korea)	
09:10-09:30	What is the Role of Brain Imaging in the Diagnosis of Dementia? Jung Lung Hsu (New Taipei Municipal TuCheng Hospital, Taiwan)	
09:30-10:30	Korea-Taiwan Joint Symposium 2 Chairpersons Dong Won Yang (The Catholic University of Korea, Republic of Korea) Chaur-Jong Hu (Taipei Medical University, Taiwan)	205 Summit Hall
09:30-09:50	What is the Appropriate Use of Amyloid Imaging Under the Situations that DMT Drugs Have Been Developed? Kee Hyung Park (Gachon University College of Medicine, Republic of Korea)	
09:50-10:10	How Can I Choose the Right Pharmacological Therapy for Alzheimer's Disease? Li-Kai Huang (Taipei Medical University Shuang-Ho Hospital, Taiwan)	
10:10-10:30	South Korean Study to Prevent Cognitive Impairment and Protect BRAIN Health through Lifestyle Intervention (SUPERBRAIN) Seong Hye Choi (Inha University College of Medicine, Republic of Korea)	
10:30-10:40	Korea-Taiwan MOU Dong Won Yang (The Catholic University of Korea, Republic of Korea) Young Chul Youn (Chung-Ang University, Republic of Korea) Cheng-Sheng Chen (Kaohsiung Medical University, Taiwan) Ming-Chyi Pai (National Cheng Kung University, Taiwan)	205 Summit Hall

10:40-10:45	Korea-Taiwan Joint Symposium Closing Remark Cheng-Sheng Chen (Kaohsiung Medical University, Taiwan)	205 Summit Hall
9:00-10:30	Session 4 : The Recent Issues in Clinical Neuropsychology Chairpersons So Young Moon (Ajou University, Republic of Korea) Ju Hee Chin (Sungkyunkwan University, Republic of Korea)	301 Grand Ballroom
09:00-09:30	Unsupervised Remote Memory Assessments in Early Stages of Alzheimer's Disease David Berron (German Center for Neurodegenerative Diseases (DZNE), Germany)	
09:30-10:00	Predictive Utility of Machine Learning Approach with Neuropsychological Test in AD Spectrum Seyul Kwak (Pusan National University, Republic of Korea)	
10:00-10:30	Digital Neuropsychological Assessments for Frontotemporal Dementia Adam Staffaroni (University of California, San Francisco, USA)	
10:50-11:30	Plenary Session III Chairperson Kun-Woo Park (Korea University, Republic of Korea)	301 Grand Ballroom
10:50-11:30	Social Cognition in Neurodegenerative Diseases Katherine P. Rankin (University of California San Francisco, USA)	
11:30-12:10	Plenary Session IV Chairperson Jee Hyang Jeong (Ewha Womans University, Republic of Korea)	301 Grand Ballroom
11:30-12:10	Creating a Worldwide platform Trial for Genetic Frontotemporal Dementia - The FTD Prevention Initiative Jonathan Rohrer (University College London, UK)	
12:10-13:00	Luncheon Symposium 2 Chairperson Yong Soo Shim (The Catholic University of Korea, Republic of Korea)	301 Grand Ballroom
12:10-12:35	Advancing Dementia Care: The Innovative Donepezil Patch and its Influence on Enhancing Compliance (Supported by Celltrion) Geon Ha Kim (Ewha Womans University College of Medicine, Republic of Korea)	
12:35-13:00	Optimizing Treatment Strategies: Focusing on Donepezil's Role in Neuroprotection and Early-Stage Alzheimer's Disease (Supported by Eisai) Hyemin Jang (Seoul National University Hospital, Republic of Korea)	


13:00-14:00	Poster Session 2	201-204
14:00-15:30	Session 5 : Update in FTD (Including FTD Cohort Study) Chairpersons Jonathan Rohrer (University College London, UK) Eun Joo Kim (Pusan National University Hospital, Republic of Korea)	301 Grand Ballroom
14:00-14:30	North American FTD Registry (ALLFTD) Howard Rosen (University of California San Francisco, USA)	
14:30-15:00	Korean FTD Registry (LEAF-FTD) Eun Joo Kim (Pusan National University Hospital, Republic of Korea)	
15:00-15:30	Familial FTD in China: Progress and Prospects Qin Chen (West China Hospital of Sichuan University, China)	
15:50-17:20	Session 6 : Pathogenesis of non-AD dementia Chairpersons Yong Jeong (KAIST, Republic of Korea) Yun Kyung Kim (KIST, Republic of Korea)	301 Grand Ballroom
15:50-16:20	Molecular Neuropathology of Chronic Traumatic Encephalopathy (CTE) Reveals Alzheimer's Disease-like Signatures Hoon Ryu (KIST, Republic of Korea)	
16:20-16:50	Molecular Mechanism of α-Synuclein in Non-AD Dementia Seung-Jae Lee (Seoul National University, Republic of Korea)	
16:50-17:20	Identifying the Early Events in ALS Pathogenesis Jeehye Park (University of Toronto, Canada)	
17:20 -	Closing Ceremony	301 Grand Ballroom

Invited Speakers



Adam Staffaroni

University of California
San Francisco, USA



Alireza Atri

Banner Sun Health Research Institute (AZ) &
Harvard Medical School (MA), USA



Charles Shieh-Yueh Yang

MagQu, Taiwan



Chi-Hun Kim

Hallym University Sacred Heart
Hospital, Republic of Korea



David Berron

DZNE, Germany



Dong-Oh Seo

Washington University in St.Louis,
USA



Eun Joo Kim

Pusan National University,
Republic of Korea



Geon Ha Kim

Ewha Womans University College
of Medicine, Republic of Korea



Hoon Ryu

KIST, Republic of Korea




Howard Rosen

University of California San
Francisco, USA



Hyemin Jang

Seoul National University
hospital, Republic of Korea



Jaeho Kim

Hallym University College of
Medicine, Republic of Korea



Jae Young Lee

ToolGen, Republic of Korea



Jan Potempa

Jagiellonian University, Poland
/ University of Louisville, USA



Jeehye Park

University of Toronto, Canada




Joel Braunstein

C2N, USA



Jonathan Rohrer

University College London, UK



Jung Lung Hsu

New Taipei Municipal TuCheng
Hospital, Taiwan



Kaj Blennow

University of Gothenburg,
Sweden



Katherine Rankin

University of California San
Francisco, US




Kee Hyung Park

Gachon University,
Republic of Korea



Keqiang Ye

Shenzhen Institute of
Advanced Technology, China



Li-Kai Huang

Taipei Medical University,
Taiwan



Qin Chen

Sichuan University, China



Seong Hye Choi

Inha University College of
Medicine, Republic of Korea



Seong-Ho Koh

Hanyang University,
Republic of Korea



Seung-Jae Lee

Seoul National University,
Republic of Korea



Seyul Kwak

Pusan National University,
Republic of Korea



Sungmin Kang

PeopleBio, Republic of Korea



Tae Kim

GIST, Republic of Korea



Yung Shuan Lin

Taipei Veterans General
Hospital, Taiwan

IC-KDA 2023

International Conference of
the Korean Dementia Association

Poster Exhibition

Poster Session

Session	Poster Session
Date	November 24 (Fri) 13:00 – 14:00 November 25 (Sat) 13:00 – 14:00
Place	201-204 (2F, BEXCO Convention Hall)

Schedule for Affixation & Removal

- 1) All presenters are requested to affix and remove their posters on the appropriate dates and time as indicated.
- 2) Each poster will be provided with one (1) panel.

Place	201-204 (2F, BEXCO Convention Hall)
Affixation	November 24 (Fri) 08:00 – 10:00
Removal	November 25 (Sat) 17:30 – 18:00

Regulations

- 1) 3M Double-sided tape and adhesive taps will be available to attach your poster to the panel. (The tape will be provided at the staff desk)
- 2) All presenters should remove their posters at the designated removal time. If not, posters will be removed by staff without notice and the organizing committee will not take responsibilities for any damages or losses of posters.
- 3) Please check the poster number on the poster panel installed at the venue and attach your poster accordingly.
- 4) The screening will be conducted during the poster session on **November 24th from 13:00 to 14:00 and November 25th from 13:00 to 14:00. The presenter should present in front of poster at that time.**

Poster Presenters

Basic Science and Pathogenesis

- PE_001** Association between Western Diet-induced Visceral Adipose Tissue Inflammation and Alzheimer's Disease Pathology in a Mouse Model
Hae Won KIM (Keimyung University Dongsan Hospital)
-
- PE_002** Immunotherapy Targeting Plasma ASM is Protective in a Mouse Model of Alzheimer's Disease
Byung Jo Choi (Kyungpook National University, Division of Biomedical Science)
-
- PE_003** Discovery of a Novel Dual-action Small Molecule that Improves Multiple Alzheimer's Disease Pathologies
HEE JI YOON (Kyungpook National University, Division of Biomedical Science)
-
- PE_007** Clinical Application of Sparse Canonical Correlation Analysis to Detect Genetic Associations with Cortical Thickness in Alzheimer's Disease
Bo-Hyun KIM (Samsung Medical Center)
-
- PE_008** Discriminative Value of CSF Space Volume for Brain Atrophy for Neurodegenerative Diseases
Yu Hyun PARK (Samsung Medical Center)
-
- PE_011** In Vivo and in Vitro Study of 17 β Estradiol against Amyloid Beta Neurotoxicity in Synaptosomes of Aging female Rats : A Therapeutic Potential Drug for Alzheimer's Disease
Pardeep KUMAR (Jawaharlal Nehru University)
-
- PE_012** Effects of the Ethanolic Extract of White Tea (*Camellia sinensis*) on Metabolic Functions in Alzheimer's Disease Rat Model
Rahul KUMAR (J K College)
-
- PE_013** Deciphering Current Advances in Neuroinflammation in Alzheimer's Disease Through a Bibliometric Approach
Rian Ka PRAJA (Faculty of Medicine, Universitas Palangka Raya)
-
- PE_014** Patient with PSEN1 Glu318Gly and Other Possible Disease Risk Mutations, Diagnosed with Early Onset Alzheimer's Disease
Seong Soo A An (Gachon University)
-
- PE_015** Diminished Microglial Uptake Leads to Increased Amyloid Beta Depositions
Bo-Ram MUN (Chonnam National University)
-
- PE_016** Generation of Human Induced Pluripotent Stem Cell (hiPSCs) based on Patients with Dementia: A Foundation for In Vitro Research
Su-Hee Jeon (Yonsei University College of Medicine)
-

PE_017 Positive Effects of Phosphatidylserine Administration in 5xFAD Mice

Yeongjin Kim (Chonnam National University)

PE_018 Effect of Mitochondrial Deficiency in AD Model

Jin-Ha KIM (Chonnam National University)

PE_019 Synapse Density and Glial Activity was Altered in the Cortex of Ndufs4 HT Mice

Jiheon LEE (Chonnam National University)

PE_020 Methylation Profiling of Neurodegenerative Diseases

Kwanghoon LEE (Seoul National University College of Medicine)

PE_021 Glial Regulation in Alzheimer's Disease Model

Bo-Ram Mun (Chonnam National University)

PE_022 Effects of Mitochondrial Defect on Early-stage Mice Behavior

Su Been PARK (Chonnam National University)

PE_023 Visualization of 3R or 4R Tau Aggregation in Live Cells Using BiFC Platform

Dong Min Kang (Korea Institute of Science and Technology)

PE_024 Clinicopathological Mismatching in a Patient Presenting with Clinical Symptoms of Parkinson's Disease

Sang Jin Kim (Busan Paik Hospital, Inje University College of Medicine)

PE_025 Progranulin Haploinsufficiency Mediates TDP43 Cytoplasmic Aggregation with Lysosomal Dysfunction in the Human Model of Microglia

Min-Young Noh (College of Medicine, Hanyang University)

PE_026 Generation of iPSCs Derived from High Risk and Low Risk Alzheimer's Disease Patients Based on Polygenic Risk Score

Seung-Yeon Lee (Samsung Medical Center)

PE_027 Unraveling the Molecular Mechanism of Flavonoid Compounds in Bajakah as Potential Dual Inhibitory Effects to Prevent Amyloid- β Plaque and Tau Protein Aggregation

Muhammad Hasanul HAQ (Faculty of Mathematics and Natural Sciences, Palangka Raya University)

Biomarkers

PE_028 MRI-based Radiomics-informed Brain Age Matrices for Classifying Mild Cognitive Impairment Converters

Hanna LU (The Chinese University of Hong Kong)

PE_029 Predictive Modeling of Personalized Clinical Outcome Trajectories in Mild Cognitive Impairment

Si Eun Kim (Inje University College of Medicine, Haeundae Paik Hospital)

- PE_030** Five-year Longitudinal Changes of Core Image Biomarkers, Amyloid and Tau, in Alzheimer's Disease Spectrum
Han-Kyeol KIM (Gangnam Severance Hospital, Yonsei University College of Medicine)
-
- PE_031** Characteristics of Discordance between Amyloid Positron Emission Tomography and Plasma Amyloid- β 42/40 Positivity
Jung-Min PYUN (Soonchunhyang University)
-
- PE_032** Aberrant GAP43 Gene Expression is Alzheimer's Disease Pathology-Specific
Jung-Min PYUN (Soonchunhyang University)
-
- PE_034** Caudate Dopamine Loss, Occipital Hypoperfusion, and Dementia Conversion in Parkinson's Disease: A Dual-phase 18F-FP-CIT PET Study
Seok Jong CHUNG (Yonsei University College of Medicine)
-
- PE_035** Predicting Superagers by Machine Learning Classification based on Gut Microbiome Features
Ha Eun Kim (Ewha Womans University)
-
- PE_036** Independent Effect of A β Burden on Cognitive Impairment in Patients with Small Subcortical Infarction
Sung Hoon KANG (Korea University Guro Hospital)
-
- PE_037** Ethnic Differences in the Effects of APOE ϵ 4 and Vascular Risk Factors on Accelerated Brain Aging
Sung Hoon KANG (Korea University Guro Hospital)
-
- PE_038** Sex-specific Relationship between Non-alcoholic Fatty Liver Disease and Amyloid- β in Cognitively Unimpaired Individuals
Sung Hoon KANG (Korea University Guro Hospital)
-
- PE_039** Altered Functional Connectivity Density against Tau Accumulation in Alzheimer's Disease
Han-Kyeol KIM (Gangnam Severance Hospital, Yonsei University College of Medicine)
-
- PE_040** Predicting Cognitive Stage Transition Using p-tau181, Centiloid, and Other Measures
Hyuk Sung KWON (Hanyang University Guri Hospital)
-
- PE_041** Extra-neurite and Intra-neurite Conductivity Maps in Patients with MCI and AD
Geon-Ho JAHNG (Kyung Hee University Hospital at Gangdong)
-
- PE_042** Gray-White Matter Boundary Tissue Volume and Its Z-Score Map in Patients with MCI and AD
Geon-Ho JAHNG (Kyung Hee University Hospital at Gangdong)
-
- PE_044** Investigating Relative PSD Difference and Coherence Analysis in rEGG of Alzheimer's Disease
Chanda SIMFUKWE (Chung-Ang University)
-
- PE_045** Distinct Effects of Cholesterol Profile Components on Amyloid and Vascular Burdens
Sung Hoon Kang (Korea University Guro Hospital)
-

- PE_046** Elevated CSF pTau as a Predictor of Rapid Cognitive Decline in Preclinical Alzheimer's Disease
Soo Hyun CHO (Chonnam National University Hospital, Chonnam National University Medical School)
-
- PE_047** Alteration of Limbic Metabolism Related to Alzheimer's Disease and Dementia with Lewy Bodies
Sung Woo KANG (Yonsei University College of Medicine)
-
- PE_048** Association between T1w/T2w Ratio in White Matter and Cognitive Function in Alzheimer's Disease
Saenal LEE (Dongguk University Ilsan Hospital)
-
- PE_049** Plasma Proteomic Profiling Predicts Proteins and Pathways Influencing Beta-Amyloid Oligomerization in the Blood
Dohyeon Kwon (Peoplebio Inc.)
-
- PE_050** Distinct Prognostic Values of Non-Alzheimer's Pathologic Changes according to Cognitive Syndromal Stages: In individuals with Alzheimer's and Concomitant Cerebrovascular Burdens
Min Young CHUN (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_051** A Case of Huntington's Disease Diagnosed by 18F-FDG-PET
Jae Young JOO (Uijeongbu Eulji Medical Center, Eulji University)
-
- PE_052** Real World One Year Estimation of the Candidates for Lecanemab in a South Korea Memory Clinic
Kyunghwa SUN (Ajou University School of Medicine)
-
- PE_053** Clinical and Pathological Validation of CT-Based Regional Harmonization Methods of Amyloid PET
Soo-Jong KIM (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_054** Reversal of Age-dependent Amyloid Real-world Prevalence across Disease Severity Spectrum in a South Korean Memory Clinic
Kyunghwa SUN (Ajou University School of Medicine)
-
- PE_055** Elevated Plasma Axon Guidance Molecule is Early Stage of Alzheimer's Disease-Specific and Associated with Amyloid and Tau Pathology
Ye Ji Lee (Hallym University, College of Medicine)
-
- PE_056** Distinct Cerebral Cortical Microstructural Changes in Idiopathic Normal-Pressure Hydrocephalus
Kyunghun KANG (School of Medicine, Kyungpook National University)
-
- PE_057** Association of Cerebrospinal Fluid (CSF) Synaptosomal-Associated Protein 25 (SNAP-25) and Cognitive Functions in Alzheimer Disease
Roland HELMIZAR (Baiturrahmah University)
-
- PE_058** Genetic Analysis of Method, Kit and Device for Risk Assessment of Alzheimer's Dementia
Ramlah RAMLAH (Universitas Sulawesi Barat)
-
- PE_059** Bibliometric Analysis on Brain Aging Biomarkers
Rian Ka PRAJA (Faculty of Medicine, Universitas Palangka Raya)
-

- PE_060** Clinical Utility of Plasma Alzheimer's Biomarkers across Asian Neurodegenerative Dementias: Cross-sectional Study in Large Multi-center Cohort
Da Eun SHIN (Samsung Medical Center)
-
- PE_061** Brain Metabolic Resilience in Alzheimer's Disease: A Predictor of Cognitive Decline and Conversion to Dementia
Hyun Woo Lee (Samsung Medical Center)
-
- PE_062** fNIRS Signal as a Potential Biomarker for White Matter Hyperintensity Progression in Patients with Subcortical Vascular Cognitive Impairment
Qi Wang (Jeonbuk National University Medical School & Hospital)
-
- PE_063** Assessing Hippocampal Atrophy as a Biomarker for Alzheimer's Disease in Indonesian Seniors
Sahnaz Vivinda PUTRI (International University Semen Indonesia)
-
- PE_064** Early Detection of Alzheimer's Disease Progression Using Multi-Modal Machine Learning
Rifaldy FAJAR (Karlstad University)
-
- PE_065** Elevated A β Oligomerization of Blood Plasma is Associated with Albuminome Profile in Alzheimer's Disease
Hongju Kim (Peoplebio Inc.)
-
- PE_066** Investigating Hub Genes and Key Pathways Implicated in Alzheimer's Disease Using Bioinformatics Analysis
Payam HOSSEINZADEH KASANI (Kangwon National University Hospital)
-
- PE_067** VR-EP-EEG-MRI Digital Biomarkers: Multi-modal Machine Learning Model for Detecting Mildcognitive Impairment
Hojin CHOI (Hanyang University College of Medicine, Guri Hospital)
-
- PE_068** Exploring Hub Genes and Critical Pathways Involved in Vascular Dementia Development
Payam HOSSEINZADEH KASANI (Kangwon National University Hospital)
-
- PE_069** Development of A Neuron-Selective Probe Incorporating into Live Neuronal Membranes
Kyu Hyeon Kim (Korea Institute of Science and Technology)
-
- PE_070** Gingitracker-1: A Fluorescent Probe Labeling the Active Site of Gingipains of P. gingivalis
Hira Aziz (KIST)
-
- PE_071** The effect of Neuroimaging Biomarkers on Gait Patterns in the Patients with Alzheimer's Disease
Min Seok BAEK (Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine)
-
- PE_072** Machine Learning Model for Mild Cognitive Impairment based on Gait and MRI Images
Yeo Jin KIM (Kangdong Sacred Heart Hospital)
-

PE_073 A Deep Learning Approach with Analysis of Acoustics and Speech for Developing MCI Prediction Model
Jin Yong Jeon (Hanyang University)

PE_074 APOE4 Genetic Influence on Blood Biomarkers and Amyloid Pathology in Subjective Cognitive Decline
Dong Won Yang (College of Medicine, The Catholic University of Korea, Seoul St. Mary's Hospital)

PE_075 Prevalence of β -Amyloid Positivity in Dementia Syndromes in Korea: Impact of Age and APOE Genotypes
Min Young CHUN (Samsung Medical Center, Sungkyunkwan University School of Medicine)

PE_076 Comparison of Enlarged Perivascular Spaces in Early-Onset and Late-Onset Alzheimer Disease-related Cognitive Impairment
Na-Yeon JUNG (Pusan National University Yangsan Hospital)

PE_077 Influence of Sleep Quality, Risk of Obstructive Sleep Apnea and Sleep Deprivation on Cortical Oxygenation in Elderly Individuals
Min Ju KANG (Veterans Healthcare Medical Center)

PE_079 Functional Connectivity Changes between Tau-accumulated Regions and Whole Brain in Alzheimer's Disease Continuum with Affective Symptoms
Taein Lee (KAIST)

PE_080 Advancing Alzheimer's Diagnosis: Creating the Gold Standard pT217 Antibody for Enhanced Sensitivity
Ji-Seon PARK (ADEL)

PE_082 The Power of Voice Using a Deep Neural Network Model for Alzheimer's Disease Detection
Young Chul YOUN (Chung-Ang University College of Medicine)

PE_083 A Reproducible Self-supervised Deep Neural Network with Dual Attention Module for Alzheimer's Disease Classification
Gia Minh HOANG (Gwangju Institute of Science and Technology)

PE_084 Lesion-network Mapping for Post-stroke Cognitive Impairment
Jae-Sung LIM (Asan Medical Center)

Clinical Manifestations

PE_085 Unveiling Alzheimer's Disease Characteristics and Follow up Changes in Heterogeneous Mild Cognitive Impairment over 5 Years
Han-Kyeol KIM (Gangnam Severance Hospital, Yonsei University College of Medicine)

PE_086 Time Perception and Memory in Mild Cognitive Impairment and Alzheimer's Disease : A preliminary Study
Sung-Ho WOO (Dongguk University)

- PE_087** Prediction of Amyloid Positivity in Patients with Subcortical Vascular Cognitive Impairment
Hasom Moon (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_088** Validity Analysis of Proposed Diagnostic Criteria for Right Temporal Variant of Frontotemporal Dementia
Na-Yeon JUNG (Pusan National University Yangsan Hospital)
-
- PE_089** Analysis of Macular Thickness and Retinal Nerve Fiber Layer by using of Spectrum Domain-optical Coherence Tomography in Patients with Alzheimer's Disease and Amnesic Mild Cognitive Impairment
Bon D. KU (International St. Mary's Hospital, College of Medicine Catholic Kwandong University)
-
- PE_090** Pathologically Confirmed Advanced Stage of Limbic Predominant Age Related TDP-23 Encephalopathy (LATE): A Case Report
Young Hee Jung (Myongji Hospital)
-
- PE_091** A Case of Typical General Paresis of Insane Mimicking Alzheimer's Disease Dementia
Kyunghwa Sun (Ajou University School of Medicine)
-
- PE_092** A Case of Pathologic Laughing and Crying with Dose-dependent Responsiveness to the Escitalopram
Kyunghwa SUN (Ajou University School of Medicine)
-
- PE_093** Two Cases of Posterior Cortical Atrophy
Yoo Jeong ROH (CHA Bundang Medical Center, CHA University)
-
- PE_094** Associative Visual Object Agnosia and Apperceptive Prosopagnosia after Aortic Dissection Surgery
Seok-Ho Choi (Pusan National University Hospital)
-
- PE_095** Semantic Variant Primary Progressive Aphasia Caused by ANXA11 p.Asp40Gly Mutation
Soo Jin YOON (Daejeon Eulji Medical Center)
-
- PE_096** The Behavioral and Psychological Symptoms Of People With Alzheimer's Disease During The COVID-19 Pandemic
Thu Tran (Military Hospital 175)
-
- PE_097** Impact of Cognitive Reserve on pTau in the Progression of Alzheimer's Disease
Yeshin Kim (Kangwon National University Hospital)
-
- PE_098** Recent Issue on Clinical Neuropsychologist in Asia: Systematic Review
Ferza ALFATH (Alumnus of Universitas Andalas)
-
- PE_099** Association of Baseline Serum Urate Levels with Longitudinal General Cognition in Non-Demented Parkinson's Disease
Jin Ho Jung (Busan Paik Hospital, Inje University College of Medicine)
-
- PE_100** Rare Strategic Vascular Cognitive Dysfunction with Isolated Left Posterior Insular Infarction
San JUNG (Hallym University Medical Center, Kangnam Sacred Heart Hospital)
-

PE_101 FDG PET Findings according to Wandering Patterns of Patients with Drug-naïve Alzheimer's Disease
YoungSoon YANG (Soonchunhyang University College of Medicine, Cheonan Hospital)

PE_102 Cerebral Perfusion Study on the Effect of Acetyl-L-carnitine in Non-demented Patients with Small Vessel Disease
Seunghee NA (Incheon St. Mary's Hospital, the Catholic University of Korea)

PE_103 Exploring Differences of Non-Dementia and Alzheimer's Disease Using Physical Activity Task: Preliminary Results
Hasom Moon (Samsung Medical Center, Sungkyunkwan University School of Medicine)

PE_104 An Autopsy Case of Familial Neuronal Intranuclear Inclusion Disease
Ahiro KIM (Ulsan University Hospital, Ulsan University College of Medicine)

PE_105 Severe Bitemporal Lobe Atrophy Derived from Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) in progressive supranuclear palsy (PSP): An Autopsy Confirmed Case Report
Eun Joo KIM (Pusan National University Hospital)

PE_106 Neuronal Intranuclear Inclusion Disease Presenting with Reversible Cerebral Vasoconstriction Syndrome: Serial Neuroimaging Findings during an 11-year follow-up
Eun Joo KIM (Pusan National University Hospital)

Dementia Care

PE_107 Machine Learning Trends in Dementia Screening and Risk Prediction
Haewon BYEON (Inje University)

PE_108 How the Caregiver Status Could Increase the Quality of Life and Nutritional Status among Elderly with Dementia
Rosinta Hotmaida Pebrianti PURBA (Learning-up Institute)

PE_109 Biological Importance of Bavachinin from *Psoralea Corylifolia* L against Parkinson's Disease through Their Inhibitory Potential on Human Monoamine Oxidase A (MAO-A) and Human Monoamine Oxidase B (MAO-B)
Dinesh Kumar PATEL (Sam Higginbottom University of Agriculture, Technology and Sciences)

PE_110 Effects of Cognitive Training System (CAVE) on Cognitive Function in Patients with Alzheimer's Dementia
Yong-Hyun LIM (Kyungpook National University)

PE_112 Biological Effect and Therapeutic Potential of Columbianadin on Blood-Brain Barrier Permeability in Medicine through Its Molecular Mechanism
Kanika PATEL (Faculty of Health Sciences, SHUATS, Prayagraj)

- PE_113** The Effectiveness of Acceptance Commitment Therapy for Distressed Family Caregiver for Patients with Dementia
Jiyoung GWAK (Haeundae Paik Hospital, Inje University)
-
- PE_115** Role of Wearable Technology and Geo-fencing Device for Alzheimer's Disease Patients in Gurugram City, India
Vikas SHARMA (IDC Research center)
-
- PE_116** Therapeutic Impact of Laughter Yoga Therapy and Clapping Exercise in Alzheimer's Disease Patients
Ranbir SINGH (Shri Maha maya vaishnav devi mandir research institute)
-
- PE_117** Perceived Barriers and Facilitators in Providing Care for Older Adults with Advanced Dementia: A Lived Experiences of Senior-year Nursing Students
Da-In Park (Hannam University)
-
- PE_118** Evaluating the Efficacy of Music Therapy in Managing Agitation and Anxiety among Indonesian Dementia Patients
Sahnaz Vivinda PUTRI (International University Semen Indonesia)
-
- PE_119** Implementation of Theory of Planned Behavior as Psychosocial Factors in the Prevention of Young Onset Dementia (YOD): Case Study in Indonesia
Vivi USMAYANTI (Universitas Sriwijaya)
-
- PE_120** Biological Potential and Therapeutic Application of Karanjin on Brain Related Disorders in Medicine through Its Molecular Mechanism
Dinesh Kumar PATEL (Sam Higginbottom University of Agriculture, Technology and Sciences)
-
- PE_121** The Influence Nonpharmacologic Approaches in Managing Dementia-Related Behaviour
Devi Yulia RAHMI (Universitas Andalas)
-
- PE_122** Investigation of TDP-43 Pathological Aggregation and Mislocalization with the Help of TDP43-BiFC Cell Line
Nataliia Lukianenko (Korea Institute of Science and Technology)
-
- PE_124** Managing Dementia with a Non-pharmacological Approach
Fitri KURNIA (Universitas Muhammadiyah Sumatera Barat)
-
- PE_126** Physical Fitness Variations based on Cognitive Function in the Elderly
Buongo CHUN (Myongji University)
-
- PE_127** Perspectives about Life-sustaining Treatment and Physician-assisted Suicide among Dementia Caregivers in Korea
YUMI LEE (Kyung Hee University)
-

PE_128 Reversible Stupor with Triphasic Waves after Polytherapy with Levetiracetam and Lamotrigine in a Dementia Patient with Seizure: A Case Report
Taeho SEO (CHA Bundang Medical Center, CHA University School of Medicine)

PE_129 Patient and Caregiver Demographic and Clinical Factors Associated with Care Burden in Early Onset Dementia
Sun Min LEE (Ajou University School of Medicine)

Neuropsychological Assessment

PE_130 Development of a Parkinson's Disease Dementia Prediction Model based on Machine Learning Technique
Haewon BYEON (Inje University)

PE_131 Digital Biomarker for Classification of Mild Cognitive Impairment in Older Adults
Ha Eun KIM (Ewha Womans University)

PE_132 Eye-Tracker Assessment of the Impact of Donepezil on Visuospatial Abilities in Mild Cognitive Impairment: Preliminary Findings
Qi Wang (Jeonbuk National University Medical School & Hospital)

PE_133 Facial Emotion Recognition Deficits in Individuals with Mild Behavioral Impairment
Bora YOON (Konyang University College of Medicine, Konyang University Hospital)

PE_134 Diagnostic Performance of a Tablet Computer-based Cognitive Screening Test for Identification of Amnesic Mild Cognitive Impairment
Miryeong Kim (Soonchunhyang University Bucheon Hospital)

PE_135 Diffusion Tensor Image Assessment in Mild Cognitive Impairment Patients with S-IADL (Seoul-Instrumental Activities of Daily Living)
Giho JEON (Pusan National University)

PE_136 The Development of Conversion Scoring System in Neuropsychological Test (Part 1): Cognitive Impairment Screening Test as a Screening Tool for Dementia: The Correlation Study of Subtest Scores with Mini Mental State Examination
Min Seong KIM (Hanyang University Hospital)

PE_137 Association between of Brain Regional Atrophy and Neuropsychological Test Performance in Patients with Definite Alzheimer's Disease
Do-yun HEO (Hanyang University Hospital)

PE_138 The Development of Conversion Scoring System in Neuropsychological Test (Part 2): Correlation Study between Subtest Scores of Seoul Neuropsychological Screening Battery and Consortium to Establish a Registry for Alzheimer's Disease in Korea
Min Seong KIM (Hanyang University Hospital)

- PE_139** Sex Differences in Items of Instrumental Activities of Daily Living in Mild Cognitive Impairment and Alzheimer's Disease Dementia
Hui Jin RYU (Konkuk University Medical Center)
-
- PE_140** Two Different Patterns of Cognitive Change in SCD Patients: Neuropsychological Perspectives
Seunghye NA (Incheon St. Mary's Hospital, the Catholic University of Korea)
-
- PE_141** Remote Neurocognitive Assessment in Clinical Practice: A Pilot Study Using a Mobile Application
Chonghwee LEE (The Catholic University of Korea, Seoul ST. Mary's Hospital)
-
- PE_142** In-Air-Time during Drawing Tests as a Potential Predictor of Amyloid Positivity in Mild Cognitive Impairment Patients
Sangheon Kim (Jeonbuk National University Medical School)
-
- PE_143** The Impact of Amyloid-beta on Cognitive Function and Neuroimaging Structure in Lewy Body Diseases.
Da-Ye Yoon (Dong-A University College of Medicine)
-
- PE_144** The Cognitive Complexity of IQ Tests Very Strongly Drives the Predictions of Phenotypic Cognitive Scores by Polygenic Cognitive Scores
Jan TENIJENHUIS (Chosun University)
-
- PE_145** The Clinical Utility of Cognitive Impairment Screening Test (CIST) in Memory Disorder Clinic
Hye Seon HAN (Samsung Medical Center, Sungkyunkwan University School of Medicine)
So Yeon Lim (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_146** Clinically Significant Decline in Preclinical and Prodromal Alzheimer's Disease
Sua KIM (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_147** Cognitive Decline During COVID-19: The Effect of Education
Hye Soo Kim (Samsung Medical Center, Sungkyunkwan University School of Medicine)
Ina Kim (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_148** Personality Associations with Cortical Thickness and Resting State Functional Connectivity in Cognitively Normal eElderly
Byung Hwa LEE (Samsung Medical Center, Sungkyunkwan University School of Medicine)
-
- PE_149** Chat-bot Based Cognitive Assessment to Screen Cognitive Impairment in older Adults
Seonyoung KIM (Ewha Womans University)
-
- PE_150** Cognitive Subgroups of Older Adults Living in Rural Korea and Their Characteristics Observed in Structural and Functional Brain Imaging: Results from the Korean Genome and Epidemiology Study (KoGES)-Cardiovascular Disease Association Study (CAVAS)
Jihyang KIM (Hallym University)
-

Pharmacological & Non-pharmacological Treatment

-
- PE_151** Effects of 40 Hz high-definition Transcranial Alternating Current Stimulation (tACS) on Subjective Sleep Quality and Cognition in Neurocognitive Disorder due to Alzheimer's Disease
Hanna LU (The Chinese University of Hong Kong)
-
- PE_152** Microcurrent as a Novel Therapeutic Approach for Alzheimer's Disease Model
Dong Rak KWON (the Catholic, University of Daegu, School of Medicine)
-
- PE_153** Effect of Tablet-based Cognitive Intervention on Cognition in Patients with Mild Cognitive Impairment: A Pilot Study
Sung Hoon KANG (Korea University Guro Hospital)
-
- PE_154** The Effectiveness of VR-based Cognitive Training Program: A Pilot Study
Eek-Sung Lee (Soonchunhyang University Bucheon Hospital)
-
- PE_156** The Effect of Home-based Cognitive Training Using Workbook and Tablet PC in Presenile Dementia Patients
Jay KWON (Changwon Fatima Hospital)
-
- PE_157** Literature Review on the Memory Intervention of Dementia
Ok Hee KIM (Chodang UNIVERSITY)
-
- PE_158** Gait Improvement Following Cerebrospinal Fluid Tap Test in Normal Pressure Hydrocephalus Patients with and without Striatal Dopaminergic Deficit
Minju KIM (Seoul National University Bundang Hospital)
-
- PE_159** Effect of Chewing Gum on Cognitive Function
So-Hee PARK (Bobath Memorial Hospital)
-
- PE_160** Optimization and In-silico Studies of Covalently-acting Tau Aggregation Inhibitors for the Treatment of Alzheimer's Disease
Lizaveta Gotina (Korea Institute of Science and Technology)
-
- PE_162** A 12-week Randomized, Blinded Clinical Trial to Compare the Cognitive Function Efficacy of Nutritional Drinks with and without Mature Silkworm Powder
Sun Min Lee (Ajou University School of Medicine)
-
- PE_163** Personalized Hippocampal Network-targeted Stimulation for Alzheimer's Disease: A Randomized Controlled Trial
Young Hee JUNG (Myoungji Hospital)
-
- PE_164** Evaluation of Efficacy and Safety Using Low Dose Radiation Therapy with Alzheimer's Disease: Interim Results of Multicenter Phase II Clinical Trial
Weon Kuu CHUNG (Kyung Hee University Hospital at Gangdong)
-

- PE_165** Exploring the Benefits of Tai Chi: Cognitive and Physical Outcomes in Adults Aged 65 and Older
Jiale Yu (MYONGJI UNIVERSITY)
-
- PE_166** High-intensity Interval Training (HIIT) as an Intervention for Sleep Quality Enhancement in Middle-aged Women
Kuan Dong (Graduate School of Myongji University)
-
- PE_167** The Effects of Agility Training on Sleep Quality in Middle-aged Women
Tenghao Yu (Myongji University)
-
- PE_168** Pilot Study on the Effects of Four-Week Healthy Dance Training on Cognitive Function and Sarcopenia-Related Factors in Elderly Women
Ying Sun (Myongji University)
-
- PE_169** The Effects of High-intensity Interval Training on Cognitive functioning in Middle-aged Women
Mingliang Ma (Myongji University)
-
- PE_170** The Role of Agility Training in Enhancing Cognitive Domains Among Middle-aged Women
Mingliang Ma (Myongji University)
-
- PE_171** Improving Elderly Cognitive Function through a Study of Pharmaceutical Chemistry Aspects involving Centella Asiatica Plants
Andi Nursanti (Wallacea University)
-
- PE_172** Telephone-based Cognitive Stimulation Program for People with Mild Dementia
Jeewon SUH (National Medical Center)
-
- PE_173** Deciphering the Dual Inhibitory Mechanisms of Sesame Bioactive Compounds against Cholinesterases for the Treatment of Alzheimer's Disease
Reny ROSALINA (Faculty of Mathematics and Natural Sciences, Palangka Raya University)
-
- PE_174** Low-Intensity Ultrasound Improves Cognitive Function in Patients with Alzheimer's Disease
Jaeho Kim (Hallym University Dongtan Sacred Heart Hospital)
-
- PE_175** Enhanced Dynamic Glymphatic Activity Using Low-intensity Ultrasound in Alzheimer's Disease
Jaeho KIM (Hallym University Dongtan Sacred Heart Hospital)
-
- PE_177** South Korean Study to Prevent Cognitive Impairment and Protect Brain Health through Multidomain Interventions via Face-to-face and Video Communication Platforms in Mild Cognitive Impairment (SUPERBRAIN-MEET): A Randomized Controlled Trial
Seong Hye CHOI (Inha University Hospital College of Medicine)
-
- PE_178** Enhancement of cognitive restoration by glia-like human mesenchymal stem cells in an animal model of vascular dementia
Ye-Jin RYU (Hanyang University Graduate School of Biomedical Science & Engineering)
-

PE_179 The Effects of Immunosuppressants on the Characteristics Properties of Wharton's Jelly-Derived Mesenchymal Stem Cells

Hyo Jin SON (Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul)

PE_180 Updates in Treatment of Parkinson's Disease: The Analysis of Nicotine as an Alternative Therapy for Parkinson's Treatment

Muhammad IRZAQ (Padang State University)

PE_181 Therapeutic Potential of Porcine Brain-Derived Peptide Mixture (PBDP) in Alzheimer's Disease: An Exploratory Study on Quantitative Electroencephalography (qEEG) Changes

Young Chul YOUN (Chung-Ang University College of Medicine)

PE_182 Did Puzzle Therapy Effect on Cognitive Functions Among Elderly with Dementia In Indonesia?

Rinita ISTIQOMAH (Yogyakarta State University)

Risk Factors, Public Health and Epidemiology

PE_183 Predicting Depression in Cognitively Impaired Older Adults after the COVID-19 Pandemic Using ICF Model

Seonjae Been (Inje University)

PE_184 Exploring Factors Influencing Suicidal Ideation among Community-dwelling Older Adults with Cognitive Impairment in South Korea Using an ICF Model

Seonjae Been (Inje University)

PE_185 Distinct Effects of Blood Pressure Parameters on Alzheimer's and Vascular Markers in 1,952 Asian Populations without Dementia

Si Eun Kim (Inje University College of Medicine, Haeundae Paik Hospital)

PE_186 Changes in Dementia Treatment Patterns Associated with National Policy in Korea among Patients with Newly Diagnosed Alzheimer's Disease between 2011 and 2017: Multicenter, Retrospective CAPTAIN Study

JunHong LEE (National Health Insurance Service Ilsan Hospital)

PE_187 Sex-specific Effects of MIND Diet on Dementia Risk: Insights from UK Biobank Data with Usual Intake Estimation

Jiyun Hwang (Seoul National University)

PE_188 Insulin Resistance and Survival in Dementia Patients: Uncovering a Significant Association

Javad ALIZARGAR (NTUNHS)

PE_189 The Correlation between Physical Fitness and Cognition Function in Korean Elderly People

Hong- Sun Song (Korean Institute of Sport Science)


- PE_190** A Systematic Review of Sedentary Behavior and Its Impact on Cognitive Function, Dementia Onset, and Subjective Cognitive Complaints in Older Adults: Passive vs. Active Sedentary Behavior
Mokyung Jung (Graduate School of Education, The University of Tokyo)
-
- PE_191** Association of Physical Fitness and Cognitive Function in Community-based Older Adults
Da-ae KIM (Korean Institute of Sport Science)
-
- PE_192** Overestimated Prediction of Alzheimer's Disease Using Polygenic Risk Score Derived from Summary Statistics
Jonghun KIM (Ilsan Hospital)
-
- PE_193** The Impact of Metabolic Health on the Relationship of Obesity with and Alzheimer's and Vascular Markers
Eun Hye LEE (Samsung Medical Center)
-
- PE_194** Age- and sex-specific Mediating Effects of Depression in the Relationship between Frailty and Cognitive Function in Korean Middle Aged and Older Adults: Results from the Korean Genome and Epidemiology Study (KoGES)-Cardiovascular Disease Association Study (CAVAS)
Haeyoon Kim (Chonnam National University Hospital)
-
- PE_195** Physical Frailty and Cognitive Functions in Older Adults Living in Rural Korea: Results from the Korean Genome and Epidemiology Study (KoGES)-Cardiovascular Disease Association Study (CAVAS)
Minji SONG (Hallym University)
-
- PE_196** Estimate of Gait Speed by Physical Fitness Test in older adults
Muncheong CHOI (Exercowork., Co.Ltd.)
-
- PE_197** Quantifying Dementia Risk Factors: A Machine Learning Analysis of Genetic Markers in Alzheimer's Disease Progression
Rifaldy FAJAR (Karlstad University)
-
- PE_198** The Association between Glucose Variability and Parkinson's Disease: Using the PPMI Datasets
Yeoju Kim (Yonsei University College of Medicine)
-
- PE_199** Particulate Matter Exposure Accelerates Tau Pathophysiology, Inflammation and Cognitive Deficits in Tau-BiFC Mice
Nicolette BOESEN (Korea Institute of Science and Technology)
-
- PE_200** Clinicopathological Correlation of Neurodegenerative Diseases in National Brain Biobank of Korea (NBBK)
Young Hee Jung (Myoungji Hospital)
-
- PE_201** Indonesian's Health Service Apps for Caregivers of Dementia Patients: Future Challenges
Vivi USMAYANTI (Universitas Sriwijaya)
-

-
- PE_202** Quality of Life Memory-Related Disease Patients in Indonesia Using Indonesia Family Life Survey
Derizal DERIZAL (IP Trisakti)
-
- PE_203** A Study on the Relationship Between Physical Activity Levels in the Elderly and the Experience of Cognitive Impairment
Daniela Andrea Gomez ortiz (Gachon University)
-
- PE_204** Does Socio-Economic And Education Matters The Patient's Quality Of Life
Mega Dwi SEPTIVANI (Politeknik Negeri Padang)
-
- PE_205** Frequency of Limbic-predominant age-related TDP-43 encephalopathy neuropathological change (LATE-NC) in a Dementia Clinic-based Cohort: A Preliminary Study
Sohyun YIM (Pusan National University Hospital)
-
- PE_206** Early Detection of Dementia Disease: How Community-based Health Centers (puskesmas) Take the Important Role among 17k Islands in Indonesia?
Rosinta Hotmaida Pebrianti PURBA (Learning-up Institute)
-
- PE_207** Effect of Dietary Habits on Alzheimer's Disease Progression
Seong Hye CHOI (Inha University College of Medicine)
-
- PE_208** Prediction Model for Mild Cognitive Impairment in Patients with Type 2 Diabetes Using an Autonomic Function Test
Heeyoung KANG (Gyeongsang National University Hospital)
-
- PE_209** Health Literacy Status of Caregivers of People with Dementia in South Korea
Gwanwook Bang (Kyunghee University, College of medicine)
-
- PE_210** Baseline Demographic and Clinical Characteristics of Longitudinal Study of Early Onset Dementia And Family Members (LEAF)
Na-Yeon JUNG (Pusan National University Yangsan Hospital)
-
- PE_211** Dementia Prevention: The Challenges and the Future from Literature Review
Zulfa SAUMIA (Universitas Jambi)
-
- PE_212** Updated Treatment for Tremor: Cutting-Edge Brain Surgery with No Cutting and Pharmacotherapy
Rani MARSYANDA (Sulthan Thata Islamic State University)
-
- PE_213** Clinical Research Platform for Multisource Brain disease (CLIMB) Registry: An National-wide Platform for Recruitment, Assessment, and Longitudinal Monitoring of Participants for Neuroscience Studies
Sujung Oh (SAIHST, Sungkyunkwan University)
-
- PE_214** Relationsip between Amyloid Burden and Sleep Characteristics in the Elderly with Subjective Cognitive Decline
Kyung Joon Jo (College of Medicine, Gachon University Gil Medical Center)
-


- PE_215** Physical Fitness, Depression, and Their Influence on Cognitive Frailty Among Community-Dwelling Elderly
Ngeemasara Thapa (Dong-A University)
-
- PE_216** Sleep Characteristics and Incident Dementia and All-cause Mortality: The Korean Genome and Epidemiology Study of Middle-aged to Older Participants
Soriul KIM (Korea University College of Medicine)
-
- PE_218** Genetic Screening of ANXA11 in Korean Patients with Frontotemporal Dementia Syndrome
Sun Min LEE (Ajou University School of Medicine)
-
- PE_219** What Physical Functions are Associated with Cognitive Decline in Community-dwelling Middle-aged and Older Adults?
KAI WANG (Dong-A University)
-
- PE_220** Association between Metabolic Syndrome and Cognitive Decline over 14 Years Modified by Sex and Inflammation
Chi-Hun KIM (Hallym University Sacred Heart Hospital)
-
- PE_221** Association of Cognitive Function and Depressive symptoms of the Elderly Residents in A Rural Community
Oh Dae KWON (Daegu Catholic University Medical Center; Daegu Catholic University School of Medicine)
-

Floor Plan

2nd Floor



3rd Floor



Information

Registration

Registration Desk

As a security requirement, we ask that you please wear your name badge at all times within the meeting venue. This will grant you access to sessions and food services.

Date	Operating Time	Place
November 24 (Fri)	08:00 – 17:30	2 nd Floor Lobby
November 25 (Sat)	07:30 – 17:30	

Registration Fee

Category		On-site	
		Full	One-day
Korean (Domestic)	Regular participants	300,000 KRW	150,000 KRW
	Trainee (Residents/Fellows) or Allied Health Professionals	100,000 KRW	50,000 KRW
	Students	30,000 KRW	15,000 KRW
Non-Korean (International)	Regular participants	250 USD	125 USD
	Trainee (Residents/Fellows) or Allied Health professionals	85 USD	40 USD
	Students	25 USD	12 USD

**Allied health professionals indicate nurse, paramedical persons, technicians, psychologists, occupational therapists, and speech therapists etc.

Name Tag

As a security requirement, please wear your name tag at all the times within the conference venues to access sessions and catering.

Speaker Information

Preview Room

The preview room will be equipped with PCs which have identical configurations to the ones in the session rooms so that the presenting authors can upload and review the presentation files ahead of their session. Please visit the preview room at least 30 minutes before the session time and submit your presentation materials.

Date	Operating Time	Place
November 24 (Fri)	08:00 – 17:30	208, 2 nd Floor
November 25 (Sat)	07:30 – 17:30	

Travel Grant Recipient

If you are nominated as a recipient for travel grant, visit the preview room with a copy of your passport after your poster presentation.

Other Information

Luncheon

Lunch will be served in the Luncheon Symposium lecture room.

Session	Date	Time	Place
Luncheon Symposium 1	November 24 (Fri)	12:10 – 13:00	301 Grand Ballroom
Luncheon Symposium 2	November 25 (Sat)	12:10 – 13:00	301 Grand Ballroom

Official & Social Program

The official & social program will proceed as shown below! We ask for your interest and attendance.

Session	Date	Time	Place
Opening Ceremony	November 24 (Fri)	10:30 – 10:50	301 Grand Ballroom
Presidential Dinner (Invited Only)	November 24 (Fri)	17:20 –	Nurimaru
Korea-Taiwan Joint Symposium Opening Remark	November 25 (Sat)	08:25 – 08:30	205 Summit Hall
Korea-Taiwan MOU	November 25 (Sat)	10:30 – 10:40	205 Summit Hall
Korea-Taiwan Joint Symposium Closing Remark	November 25 (Sat)	10:40 – 10:50	205 Summit Hall
Closing Ceremony	November 25 (Sat)	17:20 –	301 Grand Ballroom

Coffee Break

Coffee will be available as follows.


Date	Operating Time	Place
November 24 (Fri)	09:00 –	In front of 301 Grand Ballroom
	15:30 –	201-204, 2 nd Floor
November 25 (Sat)	09:00 –	201-204, 2 nd Floor
	15:30 –	

Certificate of attendance

Participants are able to receive the Certificate of attendance at MY PAGE of the IC-KDA 2023 Website from November 28.


Exhibitions

2nd Floor



Booth	Name
1	MYUNG IN PHARM.CO.,LTD.
2	MYUNG IN PHARM.CO.,LTD.
3	Duchembio
4	Chong Kun Dang Pharm.
5	Chong Kun Dang Pharm.
6	SK chemicals
7	SK chemicals
8	Lundbeck
9	Lundbeck
10	PeopleBio
11	PeopleBio
12	Handok
13	Handok

Booth	Name
14	Hanmi Pharm
15	Hanmi Pharm
16	YBRAIN
17	Bredis Healthcare Inc.
18	DNA LINK, Inc.
19	ILDONG
20	NEUROPHET, Inc.
21	Dong-A ST
22	DEEPSONBIO
23	VUNO Inc.
24	ROWAN Inc.
25	ROWAN Inc.
26	JEIL PHARMACEUTICAL

3rd Floor

Booth	Name
1	Eisai Korea Inc.
2	Eisai Korea Inc.
3	Eisai Korea Inc.
5	KDA
6	Whanin Pharm.
7	Roche
8	CELLTRIONPHARM
9	CELLTRIONPHARM
10	CELLTRIONPHARM

Booth	Name
11	DAEWOONG BIO
12	DAEWOONG BIO
13	DAEWOONG BIO
14	DAEWOONG PHARMACEUTICAL CO.,LTD.
15	DAEWOONG PHARMACEUTICAL CO.,LTD.
16	SamjinPharm
17	YUHAN
18	HYUNDAI PHARM Co., Ltd.
19	Yuyu Pharma, Inc.

Sponsors

Diamond



Platinum



Gold



Silver



Bronze



NOTE

Aricept®



ADL

Aricept, optimizing activities of daily living for AD patient^{1,2}

Behavior

Aricept, optimizing AD patient's behavioral symptoms³

Cognition

Aricept, improving AD patient's cognition significantly^{2,4}

Donepezil in AD with CVD

Aricept, improving cognition and QoL of AD with CVD patient⁵

Early Treatment

Aricept, improving cognition of AD patient with early treatment^{6,7}

- ADL : Activity of Daily Living
- AD : Alzheimer's Disease
- CVD : Cerebrovascular Disease

References 1. Gauthier S, et al. *Int Psychogeriatr* Sep;2010;22(7):83-83. 2. Roman GC, et al. *Dement Geriatr Cogn Disord* 23 Sep;2005;20:338-44. 3. Gauthier S, et al. *Int Psychogeriatr* Dec;2002;14(3):489-404. 4. Burns A, et al. *Dement Geriatr Cogn Disord* May-Jun;1999;10:237-44. 5. Frölich L, et al. *J Neurol Sci* 2002;203:204:137-9. 6. Winblad B, et al. *Dement Geriatr Cogn Disord* 27 Feb;2006;21:353-63. 7. Molinuevo JL, et al. *Arch Gerontol Geriatr* Jan-Feb;2011;52:18-22.

PRESCRIBING INFORMATION

Aricept 5 mg, 10 mg THERAPEUTIC INDICATIONS (Tablets/Daily Disintegrating tablets) For the symptomatic treatment of Alzheimer's disease. Local clinical trial results should be additionally submitted. **[PHARMACOLOGY AND METHOD OF ADMINISTRATION]** (Tablets/Daily Disintegrating tablets) **Adults** - Treatment is initiated at 5mg/day (once-a-day dosing) as described in the prescribing information. The 10mg/day dose should be maintained for at least four to six weeks, since the frequency of adverse events might be dependent on the rate of dose increase and the steady-state concentration of donepezil is achieved after three days from administration. After assessing clinical response during the period, the dose of donepezil can be increased to 10mg/day (once-a-day dosing). When increasing the dose to 10mg/day, adverse events related to digestive system should be checked carefully. Upon discontinuation of treatment, a gradual abatement of the beneficial effects of donepezil is observed. There is no rebound effect after abrupt discontinuation of the treatment. **Underweight female older than 85** - Any risk occur in these patients must frequently, careful monitoring is required. The dose should not exceed 5mg/day for underweight old female. **Children** Donepezil is not recommended for use in children. **[PRECAUTIONS FOR USE]** 1. **CONTRAINDICATIONS** 1) ARICEPT is contraindicated in patients with known to have hypersensitivity to donepezil, hydrochloride, paroxetine, dextropropriofen, or any excipients used in the formulation. 2) Pregnant, possibly pregnant and lactating women. 3) Because containing lactose, this drug should not be administered to patients with rare genetic problems such as glucose-6-phosphate deficiency or glucose-galactose malabsorption. 2. **SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE** 1) Patients with cardiac disorders such as sick sinus syndrome, intra-atrial and atrioventricular junctional conduction disturbances etc. Bradycardia and arrhythmia may occur due to vagus nerve stimulating effect. 2) Patients with a history of ulcer disease or being administered concurrent non-steroidal anti-inflammatory drugs, NSAIDs, Donepezil may aggravate the ulcer condition due to the increase of gastric acid secretion or digestive tract motility. 3) Patients with a history of asthma or obstructive pulmonary disease (Enhancement of bronchial smooth muscle contraction or bronchial secretory action make disease status more severe) 4) Patients with extrapyramidal disorders like Parkinson's disease or Parkinson's syndrome etc. (The symptom can be induced or worsened by acceleration of cholinergic nerve activity in the corpus striatum) (Last revision date: July 21, 2010).

Aricept 23 mg THERAPEUTIC INDICATIONS (Tablets/Daily Disintegrating tablets) For the symptomatic treatment of moderate to severe Alzheimer's disease. **[PHARMACOLOGY AND METHOD OF ADMINISTRATION]** (Tablets/Daily Disintegrating tablets) **Adults** - ARICEPT should be taken once daily in the evening, just prior to retiring. ARICEPT can be taken with or without food. Aricept 23 mg tablet should not be split, crushed or chewed because this may increase its rate of absorption. The recommended starting dose of Donepezil hydrochloride is 5 mg once daily. The 5mg/day dose should be maintained for at least four to six weeks since the frequency of adverse events might be dependent on the rate of dose increase and the steady-state concentration of donepezil is achieved after three days from administration. After assessing clinical response during the period, the dose of donepezil can be increased to 10mg/day (once-a-day dosing). When increasing the dose to 10mg/day, adverse events related to digestive system should be checked carefully. A dose of 23 mg once daily can be administered once patients have been on a dose of 10mg once daily for at least 3 months. Upon discontinuation of treatment, a gradual abatement of the beneficial effects of donepezil is observed. There is no rebound effect after abrupt discontinuation of the treatment. This medicine is a orally disintegrating tablet, can't be administered with or without water by melting it on the tongue. **[PRECAUTIONS FOR USE]** 1. **CONTRAINDICATIONS** 1) ARICEPT is contraindicated in patients with known to have hypersensitivity to donepezil, hydrochloride, paroxetine, dextropropriofen, or any excipients used in the formulation. 2) Pregnant, possibly pregnant and lactating women. 3) Because containing lactose, this drug should not be administered to patients with rare genetic problems such as glucose-6-phosphate deficiency or glucose-galactose malabsorption. 2. **SPECIAL WARNINGS AND SPECIAL PRECAUTIONS FOR USE** 1) Patients with cardiac disorders such as sick sinus syndrome, intra-atrial and atrioventricular junctional conduction disturbances etc. Bradycardia and arrhythmia may occur due to vagus nerve stimulating effect. 2) Patients with a history of ulcer disease or being administered concurrent non-steroidal anti-inflammatory drugs, NSAIDs, Donepezil may aggravate the ulcer condition due to the increase of gastric acid secretion or digestive tract motility. 3) Patients with a history of asthma or obstructive pulmonary disease (Enhancement of bronchial smooth muscle contraction or bronchial secretory action make disease status more severe) 4) Patients with extrapyramidal disorders like Parkinson's disease or Parkinson's syndrome etc. (The symptom can be induced or worsened by acceleration of cholinergic nerve activity in the corpus striatum) (Last revision date: June 23, 2010).

HealthCare Provider only

Power
Core
Consistent


[illegible]

* 이 내용을 허가사항을 요약한 것으로 자세한 정보는 제품의 첨부문서 또는 <http://nedrug.mfds.go.kr>를 확인하십시오.

DONG-A ST



edarbi[®]
azilsartan medoxomil
40 mg•80 mg tablets



Cognitive enhancers

CEREBRAIN® Inj

【Indications】

Senile dementia (Alzheimer's type, Vascular dementia)
Post-stroke brain dysfunction, Trauma to the Skull
(Concussion, Cerebral contusion)

【How to use】

Senile dementia (Alzheimer's type, Vascular dementia) : 10–30ml
Ischemic stroke : 30–50ml
Hemorrhagic stroke : 30ml
Trauma to the Skull (Concussion, Cerebral contusion) : 20–30ml / 50ml

Intravenous infusion is recommended from 10ml,
and it is mixed with 0.9% NaCl, Ringer's solution, 5% Glucose (or dextran 40).
Vitamins and cardiovascular drugs may be given concomitantly with CEREBRAIN®
but the drugs should not be mixed with CEREBRAIN® in the syringe.



CKD GLIATILIN HELPS YOU KEEP MEMORIES

KEEP YOUR TIME



CKD
GLIATILIN®



**We are tirelessly dedicated to restoring brain health,
so every person can be their best.**

Lundbeck is a Global Pharmaceutical Company focusing exclusively on brain diseases,
recognized for having helped hundreds of millions of people with brain diseases.



All-ways, Exelon®

For AD, PDD dementia patients with subcortical symptoms*

EXELON

*Exelon은 AD 뿐만 아니라 PDD 환자의 치매 증상의 치료에 적응증이 있으며 BPSD, parkinsonism, visual hallucination와 같은 subcortical symptom이 동반된 AD, PDD 환자에서 효과를 보였습니다.¹⁻⁴

References. 1. Gauthier S, et al. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract. 2007 Jun;61(6):886-95. 2. Emre M et al, N Engl J Med 2004;351:2509-18. 3. Burn D, et al, Movement disorder, 2006, 21(11):1898-1907. 4. [엑셀론] 식품의약품안전처 의약품통합정보시스템(nedrug.mfds.go.kr)

Product Information * 상세 제품 정보는 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(<https://nedrug.mfds.go.kr>)을 통해 확인하여 주시기 바랍니다.



엑셀론 캡슐 1.5 mg



엑셀론 캡슐 3.0 mg



엑셀론 캡슐 4.5 mg



엑셀론 캡슐 6.0 mg



엑셀론 패치 6



엑셀론 패치 10



엑셀론 패치 15

Convenience of once daily GINEXIN-F Tab. 240mg



GINEXIN-F Tab, 240mg Prescribing Information¹

[PRODUCT NAME] Ginexin-F Tab, 240mg(Ginkgo biloba ext.) **[ACTIVE INGREDIENT AND ITS CONTENT]** 1 film-coated tablet contains: Ginkgo biloba ext.(EP)-240mg **[INDICATION AND USAGE]** Ginexin-F Tab, 240mg used when mental performance declines with symptoms such as lack of concentration, forgetfulness, dizziness (with Arteriosclerosis complaints) **[DOSAGE AND ADMINISTRATION]** (Adults over 18 years) Take 1 film-coated tablet whole with a little liquid once a day, it can be taken independently of meals. **[CONTRAINDICATIONS]** 1) Hypersensitivity to Ginkgo biloba ext. or other components of the drug 2) There are insufficient studies on the use of Ginexin-F Tab, 240mg in children and adolescents, Ginexin-F Tab, 240mg should therefore be used in children and Adolescents under 18 years of age are not used, 3) pregnancy 4) Ginexin-F Tab, 240mg contains lactose, Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose maldigestion should not take this medicine. **[INTERACTIONS]** 1) 1. Ginkgo biloba extracts are administered simultaneously with anti-coagulant drugs (e.g., phenprocoumon, warfarin, clopidogrel, acetylsalicylic acid and other non-steroidal anti-inflammatory drugs), their enhancement of the effect cannot be excluded, 2) As with any medicinal product, it cannot be ruled out that Ginkgo biloba extracts influence the metabolism of various other medicinal products via cytochromes P450, 3A4, 1A2, 2E1 and 2C9, which in turn can change the effectiveness and / or the duration of action, 3) Ginkgo biloba extracts are taken at the same time as calcium antagonists such as nifedipine and diltiazem, there is a risk of higher levels of these substances due to the influence on bioavailability, 4) taken at the same time as oral theophylline, there is a risk of lower active levels by influencing the elimination, Careful monitoring and possibly dose adjustments are therefore required. **[PRECAUTIONS]** 1) Medical advice should be sought in patients with bleeding disorders or if concurrently taking medications that increase the risk of bleeding, 2) lactation (it is not known whether the ingredients of ginkgo biloba extracts get into breast milk) 3) It cannot be ruled out that the use of ginkgo preparations in patients with epilepsy may promote the occurrence of further seizures. **[MANUFACTURER]** Richwood Trading Company, LTD, 120 Juseokgongdan 3-eil Hyangnam-eu, Hwasong-si, Gyeonggi-do **[DISTRIBUTOR]** SK chemicals, 310 Pongpo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 2020,12,24
※ Please refer to the package insert for further details. The latest approved label is available on the website following: Ministry of Food and Drug Safety (<http://ndrug.mfds.go.kr>)

Over-the-counter drug

References. 1. H. R. et al., Efficacy and Safety of a Once-Daily Formulation of Ginkgo Biloba Extract Egb 761 in Dementia With Neuropsychiatric Features: A Randomized Controlled Trial, H. J. Geriatr Psychiatry, 2012;26(11):1189-94, 2. Gross-Kepnerke B. et al., Effects of Ginkgo Biloba Special Extract Egb 761® in Very Mild Cognitive Impairment (MCI), Neuroscience & Medicine, 2012;248-56, 3. Beck SM et al., Effects of Ginkgo biloba extract Egb 761® on cognitive control functions, mental activity of the prefrontal cortex and stress reactivity in elderly adults with subjective memory impairment—a randomized double-blind placebo-controlled trial, Hum Psychopharmacol, 2016;31(3):227-42, 4. Ginexin-F Tab, 240mg Approval data, Ministry of Food and Drug Safety [Cited 2021.07.16] Available from: <https://ndrug.mfds.go.kr/>

GINEXIN-F Tab.
240mg
Ginkgo biloba ext.



SAVE THE QUALITY TIME WITH EBIXA®

The combination therapy of Ebixa® and AChEI is more effective in delaying the progression of AD symptoms and maintaining ADL compared to AChEI monotherapy.¹

Reference 1. Atri et al., Alzheimer Dis Assoc Disord. 2008;22(3):209-221.

Ebixa® 10mg, 20mg Memantine Hydrochloride [ETC, imported drug]

The new Alzheimer's treatment Ebixa®, developed by Merz Pharmaceuticals in Germany, is indicated for the treatment of moderate to severe Alzheimer's disease and is sold worldwide by H. Lundbeck A/S of Denmark. Memantine, the active substance of this drug, is a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, a subtype of glutamate receptors. It is a therapeutic drug with a new mechanism of action that shows the therapeutic effect of Alzheimer's Disease by maintaining physiological activities related to learning and memory ability by antagonizing NMDA receptors, which are pathologically activated by elevated glutamate in synapses. **[Ingredients and quantity]** Ebixa® 10mg Tablet: 1 tablet (156 mg) of this drug. Active ingredients: Memantine hydrochloride (HCl) - 10 mg (equivalent to memantine 6.33 mg). Additives: Microcrystalline cellulose, Magnesium stearate, Opadry yellow (E8325255), croscarmellose sodium, colloidal silicon dioxide. Ebixa® 20mg Tablet: 1 tablet (312 mg) of this drug. Active ingredients: Memantine Hydrochloride (HCl) - 20 mg (equivalent to memantine 16.62 mg). Additives: Microcrystalline cellulose, Magnesium stearate, Opadry Pink (E8325482), croscarmellose sodium, colloidal silicon dioxide. **[Description of Ebixa® Tablets]** Ebixa® 10mg Tablet: The light yellow to yellow oval film coated tablet with split lines on both sides. "H" is engraved on one side and "10" is engraved on the other side. Ebixa® 20mg Tablet: The pink oval film coated tablet has "20" engraved on one side and "MEMH" engraved on the other. **[Efficacy]** Treatment of Moderate to Severe Alzheimer's Disease **[Dosage and Administration]** Treatment should be initiated by a physician with experience in the diagnosis and treatment of Alzheimer's dementia and should only be started if the caregiver is able to regularly monitor the patient's medication intake. Diagnosis should be made according to current guidelines. The clinical efficacy of this drug and the patient's compliance with treatment should be evaluated regularly. This medicine is taken orally once daily and should be taken at the same time each day. If necessary, the dosage may be increased to a twice-daily regimen. The medication can be taken with or without food. 1. Adult - Dose escalation: The maximum daily dose is 20 mg. To minimize the risk of adverse reactions, the dose should be increased by 5 mg per week for the first three weeks until reaching the maintenance dose (5 mg per day for the first week from day 1 to day 7, 10 mg per day for the second week from day 8 to day 14, 15 mg per day for the third week from day 15 to day 21, 20 mg per day from the fourth week onwards). Maintenance Dose: The recommended maintenance dose is 20 mg per day, 2. Elderly - Based on clinical data, the recommended dose for elderly patients aged 65 and older is 20 mg per day, 3. Patients with renal impairment - No dose adjustment is required in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance: 30-49 mL/min), the daily dose should be reduced by 10 mg. If the patient tolerates the medication well after at least 7 days, the dose can be increased according to the standard dose escalation method, up to 20 mg per day. In patients with severe renal impairment (creatinine clearance: ≤29 mL/min), the daily dose should be reduced by 10 mg, 4. Patients with hepatic impairment - No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). There is no data on the use of memantine in severe hepatic impairment patients, so it is advisable not to administer this drug to such patients. **[Precautions for use]** Do not administer to the following patients: 1) Patients with hypersensitivity to the ingredients of this drug 2) Patients with severe hepatic impairment 3) Patients with severe renal impairment (creatinine clearance < 5 mL/min) 2. Administer with caution to the following patients: 1) Patients with epilepsy, past convulsive patients, and patients with a predisposition to epilepsy 2) Patients concomitantly receiving NMDA (N-methyl-D-aspartate) receptor antagonists such as amantadine, ketamine, or dextromethorphan. Since these drugs act on the same receptors as this drug, the rate of side effects (mainly related to the central nervous system) may increase or the duration of side effects may be prolonged, so concomitant administration is not recommended. 3) Patients with factors that can increase urinary pH. These include sudden dietary changes from a meat-based to a vegetarian diet, large intake of alkaline beverages, or severe urinary tract infections caused by Proteus bacteria or renal tubular acidosis (RTA). 4) Patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension. These patients were mostly excluded from clinical trials, so there is no data available for them. 3. Adverse reactions: A clinical trial included 1,784 patients treated with Ebixa® and 1,595 patients treated with a placebo, which was conducted for patients with mild to severe Alzheimer's disease, the overall incidence of adverse reactions was similar between the two groups, and the severity of adverse reactions was generally mild to moderate. The most frequently occurring adverse reactions in the group that received Ebixa® were dizziness (3.3% vs. 5.0%), headache (5.2% vs. 3.9%), constipation (4.6% vs. 2.6%), drowsiness (3.4% vs. 2.2%), and hypertension (4.1% vs. 2.8%). **[Storage]** Airtight containers, room temperature (1-30°C storage). (Expiry date) 48 months from the date of manufacture. **[Packaging Unit]** Ebixa® 10mg Tablet: 56 tablets/box (14 tablets/PTP x 4). Ebixa® 20mg Tablet: 28 tablets/box (14 tablets/PTP x 2). **[Product Inquiries]** Lundbeck Korea Co., Ltd. Customer Service Hotline: +82-2-431-6600 **[Importer/Seller]** 19th Floor, Korea Advertising Culture Center, 137, Olympic-ro 35-gil, Songpa-gu, Seoul, Korea **[Legal Manufacturer]** H. Lundbeck A/S Østlævej 9, 2500 Valby, Denmark **[Manufacturer]** Rotendorf Pharma GmbH Osterfelder Strasse 51-61, D-59320 Enigerloh, Germany **[Packaging and Inspection]** Merz Pharma GmbH & Co. KGaA Ludwigstrasse 22, D-64354 Reinheim, Germany Final revision date of the manual: May 2, 2022. 8. Changes made after this document's final revision date can be checked on our website (www.lundbeck.com/kr). 9. Please refer to the product description for detailed product information.

Premium Treatment for Dementia

RISELTON[®]

Cap.

Patch

Rivastigmine

Cap. 1.5mg, 3mg, 4.5mg, 6mg

Patch 5, 10, 15



Manufactured & Distributed by
MYUNG IN PHARM. CO., LTD.
www.myunginph.co.kr

Insulin sensitizer from Korea Duvie, Duvimet XR tab.

- Strong and sustained glucose lowering effect
- Metabolic syndrom, Lipid profile improvement effect
- Preserving β -cell function

 **Duvie®** tab.  **DuviMet® XR** tab.

[illegible]

듀비에트서발정 허가사항

[illegible]



**We are tirelessly dedicated to restoring brain health,
so every person can be their best.**

Lundbeck is a Global Pharmaceutical Company focusing exclusively on brain diseases,
recognized for having helped hundreds of millions of people with brain diseases.



All-ways, Exelon[®]

For AD, PDD dementia patients with subcortical symptoms*

EXELON

*Exelon은 AD 뿐만 아니라 PDD환자의 치매 증상의 치료에 적응증이 있으며 BPSD, parkinsonism, visual hallucination와 같은 subcortical symptom이 동반된 AD, PDD 환자에서 효과를 보였습니다.¹⁻⁴

References. 1. Gauthier S, et al. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease. *Int J Clin Pract.* 2007 Jun;61(6):886-95. 2. Emre M et al, *N Engl J Med* 2004;351:2509-18. 3. Burn D, et al, *Movement disorder*, 2006, 21(11):1899-1907. 4. [엑셀론] 식품의약품안전처 의약품통합정보시스템(nedrug.mfds.go.kr)

Product Information ※ 상세 제품 정보는 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(<https://nedrug.mfds.go.kr>)을 통해 확인하여 주시기 바랍니다.



엑셀론 캡슐 1.5 mg



엑셀론 캡슐 3.0 mg



엑셀론 캡슐 4.5 mg



엑셀론 캡슐 6.0 mg



엑셀론 패치 5



엑셀론 패치 10



엑셀론 패치 15

HANDBOK

(주)한독 서울시 강남구 테헤란로 132

TEL 02-527-5114 FAX 02-527-5001 www.handok.co.kr

KCPH230102
KPS230123089



SAVE THE QUALITY TIME WITH
EBIXA®

Ebixa® 20mg is widely prescribed for AD patients and has been approved in more than 75 countries.

Reference Worldwide Marketing Authorisation Status (Sep 2022)

Ebixa® 10mg, 20mg Memantine Hydrochloride [ETC, imported drug]

New Alzheimer's treatment: Edo[®], developed by Merz Pharma, is Germany, is indicated for the treatment of moderate to severe Alzheimer's disease and is sold worldwide by H. Lundbeck A/S of Denmark. Meanwhile, the active substance of this drug, is a non-competitive antagonist of N-methyl-D-aspartate (NMDA) receptors, a subtype of glutamate receptor. It is a therapeutic drug with a new mechanism of action that shows the therapeutic effect of Alzheimer's disease by maintaining physiological activities related to learning and memory ability by antagonizing NMDA receptors, which are pathologically affected by elevated glutamate in synapses. **[Ingredients and quantity]** Edo[®] 10mg tablet [Tablet] 56mg of this drug. Active ingredients: Memantine hydrochloride (HCl), 56 mg (equivalent to memantine 16.56 mg). Excipients: Microcrystalline cellulose, Magnesium stearate, Opadry Pink (E837492), croscarmellose sodium, colloidal silicon dioxide. **[Description of Edo[®] Tablets]** Edo[®] 10mg Tablet: The light yellow to off-white film-coated tablets with linear markings. "M" is engraved on one side and "10" is engraved on the other side. Edo[®] 20mg Tablet: The pink oval film-coated tablet has "20" engraved on one side and "EMZ" engraved on the other. **[Efficacy]** Treatment of Moderate to Severe Alzheimer's Disease. **[Dosage and Administration]** Treatment should be initiated by a physician with experience in the diagnosis and treatment of Alzheimer's dementia and should only be started if the caregiver is able to regularly monitor the patient's medication intake. Diagnosis should be made according to clinical criteria. Patients should be treated with Edo[®] 10mg tablets twice daily with or without food. In patients with mild to moderate impairment, the recommended dose is 10 mg per day for the first three weeks until reaching the maintenance dose of 20 mg per day for the first week from day 1 to day 10, 7 mg per day for the second week from day 8 to day 14, 15 mg per day for the third week from day 15 to day 21, 20 mg per day from the fourth week onwards. Maintenance Dose: The recommended maintenance dose is 20 mg per day. **Elderly:** Based on clinical data, the recommended dose for elderly patients aged 65 and older is 20 mg per day. **Patients with renal impairment:** No dose adjustment is required in patients with mild renal impairment (creatinine clearance ≥ 30 mL/min). In patients with moderate to severe renal impairment (creatinine clearance < 30 mL/min), the recommended dose is 10 mg per day. **Patients with hepatic impairment:** No dose adjustment is required in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). There is no data on the use of memantine in severe hepatic impairment; thus, it is advisable not to administer this drug to such patients. **[Precautions for use]:** Do not administer to the following patients: 1) Patients with hypersensitivity to the ingredients of this drug. 2) Patients with severe hepatic impairment. 3) Patients with severe renal impairment (creatinine clearance < 5 mL/min). 2) Administer with caution to the following patients: 1) Patients with epilepsy, past convulsive patients, and patients with a predisposition to epilepsy. 2) Patients with low blood pressure. **[Contraindications]** Concomitant administration of Edo[®] 10mg tablets with drugs that may increase urinary pH is contraindicated. These include salicylate dietary changes from a meat-based to a vegetarian diet, large intake of alkaline beverages, or severe urinary tract infections caused by Proteus bacteria or renal tubular acidosis (RTA). 4) Patients with recent myocardial infarction, congestive heart failure, or uncontrolled hypertension. These patients were mostly excluded from clinical trials, so there is no data available for them. 3) Adverse reactions: A total of 1,798 patients treated with Edo[®] 10mg and 1,555 patients treated with placebo, which was conducted for patients with mild to severe Alzheimer's disease, the overall adverse reaction rates were similar between the two groups, and the severity of adverse reactions was also comparable. The most common adverse reactions observed in both groups were dizziness (10.2% vs 10.1%), headache (7.9% vs 7.8%), constipation (7.8% vs 7.8%), and fatigue (7.8% vs 7.8%). **[Storage]** Airtight containers, room temperature (13-30°C storage). [Expiration date] 48 months from the date of manufacture. **[Packaging Unit]** Edo[®] 10mg Tablet 56 tablets/box [4 tablets/PPT x 4], Edo[®] 20mg Tablet 28 tablets/box [4 tablets/PPT x 2]. **[Product Inquiry]** Lundbeck Korea Co., Ltd. Customer Service Hotline: +82-2-431-6600 | **Importer/Supplier:** 10th Floor, Korea Advertising Culture Center, 127, Olympic-ro #3-38, Songpa-gu, Seoul, Korea | **Legal Manufacturer:** H. Lundbeck A/S Østlævej 9, 2600 Valby, Denmark | **Manufacturer:** Lundbeck A/S, Artvejsvej 55, DK-2650 Lyngby, Denmark | **Pharmaceutical Sales Representative:** H. Lundbeck A/S, Østlævej 9, 2600 Valby, Denmark | **[Packaging and Inspection]** Each box contains 56 tablets. **[Additional Information]** This document is for informational purposes only. It does not constitute medical advice. For more information, please visit our website: www.lundbeck.com. **[Disclaimer]** All trademarks are the property of their respective owners. © 2024 H. Lundbeck A/S. All rights reserved. Final revision date of the manual: May 2, 2024. 18 Changes made after approval.

“NMDA Receptor Antagonist”

Fello[®] Tab.
OD Tab.

Memantine HCl

Tab. 5mg 10mg OD Tab. 5mg 10mg 20mg



Manufactured & Distributed by
MYUNG IN PHARM. CO., LTD.
www.myunginph.co.kr

A New Perspective On Alzheimer's Disease (AD)

Aid in the diagnosis of Alzheimer's disease in blood

The background of the slide is a photograph of a laboratory setting. A person wearing white nitrile gloves is holding a small, clear plastic test tube with a purple cap. The tube has a scale from 1 to 5 and contains a red liquid. A large, semi-transparent purple circle is overlaid on the tube. In the background, another test tube and a pipette are visible on a lab bench.

**Discovering ongoing pathology
in advance of symptoms**

**Superior clinical utility and value
approved and validated by MFDS and nHTA**

**High diagnostic accuracy and concordance rate
in comparison with pre-existing standard measures**



Optimal option of MCI & Post Stroke

Cholinate Soft
Cap.

(Choline alphoscerate 400mg)



Superbrain is a world-class dementia prevention program, specifically designed and developed to suit the characteristics of the elderly in Korea (FINGER program)

The study was titled SUPERBRAIN (SoUth Korean study to PrEvent cognitive impairment and protect BRAIN health through lifestyle intervention in atrisk elderly people) and was the only study in Korea to participate in the WW-FINGERS network



1

Program with digitally-based large-scale clinical results

Cognitive ability improvement effects have been confirmed through a three-year clinical trial involving 152 participants, sponsored by the Ministry of Health and Welfare.

2

Can be used without restrictions on the number of people or space

Can be used in various situations, including personal training, group training, and non-face-to-face training

3

Program that can secure real-time data

Providing optimal customized content for each user using digital technology

We Optimize Surroundings with
Digital Therapeutics

We contribute to the world for Humanity

ROWAN



I prescribe what's best.

**the more I think of my patients
the more I contemplate the efficacy**

I put my patient's quality of life first.

I put my patient's families first.

I put my patient's safety first.

That is why I prescribe Gliatamin,
the No.1 prescribed brain function enhancer.

Cerebrovascular Disease
Cerebral Metabolism Medication

GLIATAMIN®

Tab./Inj.
Soft cap.
Syrup

- Improvements in Cognitive Functions ^{1,2,3,4,5}
- Improvements in Behavioral Disturbances and Depression ^{2,3,5}
- Delays in Symptom Progression of Dementia ⁵

[Active Ingredient]

1 tablet/capsule/pouch contains; Choline Alfoscerate 400mg
1 ampoule (4ml); Choline Alfoscerate 1g

[Therapeutic Indications]

- Secondary symptoms, degeneration, or degenerative organic psychosis caused by cerebrovascular deletion: memory loss, mental aberration, disorientation caused by decrease of will and spontaneity, decrease of will and spontaneity, decrease of concentration

[Dose and Administration]

- Administered orally at the dose of 400mg of Choline Alfoscerate 2-3 times a day.
The dose can be increased or decreased In accordance with the patient's symptoms.
- Administered via intramuscular or intravenous injection at the dose of 1g of Choline Alfoscerate once a day.
The dose can be increased or decreased In accordance with the patient's symptoms.

[Warning and Precautions]

Do not use this product:

- 1) If the patient is hypersensitive to this drug or its ingredients;
- 2) If the patient is pregnant or is likely of being pregnant.

[Expiry Date]

Tablet/Capsule/Syrup: 24 months from the manufacturing date
Ampoule: 36 months from the manufacturing date

* See the package leaflet for further information. * Daewoong Bio website (www.daewoongbio.co.kr) / Consumer Consulting (080-789-0787)



Start EARLY

with ARICEPT

 **Aricept**[®]

Start early treatment with ARICEPT[®] and help preserve cognitive function and independence longer in Alzheimer's patients.¹

REFERENCE 1. Seltzer B, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial. *Arch Neurol*. 2004; 61(12):1852-6.